Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ARAZLO 0.045% LOTION

tazarotene
$11.4529per GM
High Outlier

Strength

.45 mg/g

Manufacturer

Bausch Health US LLC

NDC

00187209845

Classification

Brand

Dosage Form

LOTION

Route

TOPICAL

Last Updated

9/17/2025

Active Ingredients

TAZAROTENE

Approval Type

New Drug (NDA)

FDA Application

NDA211882

On Market Since

12/19/2019

Pharmacological Classes

Retinoid
Retinoids

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

-0.0%

3Y

+4.3%

5Y

N/A

All

+20.3%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

DIFFERIN 0.1% GEL
Brand
00299491045•Galderma Laboratories, L.P.
$0.4639
per GM
DIFFERIN 0.1% GEL
Brand
00299491015•Galderma Laboratories, L.P.
$0.7045
per GM
RETIN-A 0.05% CREAM
Brand
00187516245•Bausch Health US LLC
$0.7904
per GM
RETIN-A 0.025% CREAM
Brand
00187516045•Bausch Health US LLC
$0.7904
per GM
RETIN-A 0.025% CREAM
Brand
00187516020•Bausch Health US LLC
$0.7907
per GM
RETIN-A 0.05% CREAM
Brand
00187516220•Bausch Health US LLC
$0.7914
per GM
RETIN-A 0.01% GEL
Brand
00187517245•Bausch Health US LLC
$0.9570
per GM
RETIN-A 0.025% GEL
Brand
00187517045•Bausch Health US LLC
$0.9582
per GM
RETIN-A 0.025% GEL
Brand
00187517015•Bausch Health US LLC
$0.9592
per GM
RETIN-A 0.1% CREAM
Brand
00187516420•Bausch Health US LLC
$0.9594
per GM

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy